Finnish researchers discover genes inhibiting the spread of prostate cancer
The research team of Professor Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) screened dozens of prostate cancers using gene silencing and discovered mechanisms of that inhibit the spread of cancer cells.
Published in the Journal of Cell Science, the study shows that cancer cell adhesive activity, which is easy to measure in a laboratory setting, is directly linked to the ability of the cancer cells to metastasise. As a result, screening for regulators of cancer cell activity can lead to the discovery of new candidates for pharmaceutical development.
The study describes dozens of new regulators of cancer cell activity; employing gene silencing mechanisms on two of these regulators (CD9 and MMP8) was found to have a direct impact on the spreading of cancer cells.
In the study, researchers Teijo Pellinen and Juha Rantala from Professor Ivaska's research team utilised the cell spot micro array technology developed by VTT. The method allows researches to study the impacts of all genes in an entire genome in a single experiment.
Original publication
Pellinen T, Rantala JK, Arjonen A, Mpindi JP, Kallioniemi O, Ivaska J.; "A functional genetic screen reveals new regulators of β1-integrin activity."; J Cell Sci. 2012 Feb 1;125(Pt 3):649-61.
Original publication
Pellinen T, Rantala JK, Arjonen A, Mpindi JP, Kallioniemi O, Ivaska J.; "A functional genetic screen reveals new regulators of β1-integrin activity."; J Cell Sci. 2012 Feb 1;125(Pt 3):649-61.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Major 'third-hand smoke' compound causes DNA damage
Use it or lose it - Research illuminates a molecular mechanism for why a stimulating environment may protect against Alzheimer's Disease
IDT is awarded further funding for gene silencing research - Unique U1 adapters silence RNAi refractory genes
Sanofi-aventis to acquire TargeGen Inc. - Development of oral potent oncology medicines for the treatment of hematological malignancies
Eurofins acquires biopharmaceutical company Alphora Research, Inc.

Materials Research Says Yes to Wood - Green alternatives to fossil raw materials: Bio-based materials are expected to reduce pollution and drive the shift to a more sustainable economy

Parasitology: Mother cells as organelle donors
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs - New effort will search for potential therapies targeting the most common mutation of cystic fibrosis
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
